Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $42.33

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received a consensus recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $42.33.

KROS has been the subject of several recent research reports. HC Wainwright decreased their target price on shares of Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. William Blair lowered Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Wells Fargo & Company decreased their price target on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, February 27th. Finally, Truist Financial cut their price objective on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, December 23rd.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Geode Capital Management LLC increased its position in Keros Therapeutics by 6.8% during the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock worth $42,146,000 after acquiring an additional 46,041 shares during the period. Charles Schwab Investment Management Inc. grew its position in Keros Therapeutics by 14.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after purchasing an additional 32,492 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Keros Therapeutics during the 4th quarter worth about $388,000. Barclays PLC raised its position in shares of Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after buying an additional 35,022 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Keros Therapeutics in the fourth quarter valued at about $461,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Trading Down 1.8 %

Shares of NASDAQ:KROS opened at $10.79 on Friday. The business has a fifty day simple moving average of $11.15 and a 200 day simple moving average of $34.30. Keros Therapeutics has a 1 year low of $9.78 and a 1 year high of $72.37. The firm has a market cap of $437.66 million, a price-to-earnings ratio of -2.07 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. On average, sell-side analysts forecast that Keros Therapeutics will post -4.74 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.